NCT00423202View on ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

PHASE3CompletedINTERVENTIONAL

Enrollment

186

Participants

Timeline

Start Date

December 31, 2003

Study Completion Date

October 31, 2005

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

ambrisentan

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY

NCT00423202 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension. | Biotech Hunter | Biotech Hunter